{"id":2078,"date":"2015-03-10T19:49:47","date_gmt":"2015-03-10T11:49:47","guid":{"rendered":"http:\/\/www.appliedpsyj.org\/journal\/?p=2078"},"modified":"2015-03-11T16:47:49","modified_gmt":"2015-03-11T08:47:49","slug":"parkinsons-disease-with-dementia-and-dementia-with-lewy-bodies","status":"publish","type":"post","link":"https:\/\/www.appliedpsyj.org.tw\/journal\/?p=2078","title":{"rendered":"Parkinson’s Disease with Dementia and Dementia with Lewy Bodies"},"content":{"rendered":"

Chu-Yun Huang<\/strong>
\nDepartment of Clinical pharmacy, Taipei Medical University
\nChin-Chang Huang<\/strong>
\nDepartment of Neurology, Chang Gung memorial Hospital College of medicine, Chang Gung University<\/p>\n

Patients with Parkinson\u2019s disease with dementia (PDD) or dementia with Lewy bodies (DLB) have similar clinical manifestations including cognitive impairment, behavior disorders, autonomic dysfunction, and parkinsonian features. The difference between these two disorders is based on the one year rule: PDD is diagnosed while the onset of dementia occurs 12 months or more after the onset of parkinsonism and DLB is diagnosed if cognitive impairment precedes or follows the parkinsonian features within 12 months. Both share the same pathological features including Lewy bodies in the cortex, limbic system, neocortical area and brainstem. The diagnostic criteria of DLB include three core features of parkinsonism, fluctuation of cognition, and visual hallucination. Three additional suggestive features include REM sleep behavior disorder, neuroleptic sensitivity, and an abnormal dopamine transporter scan. Although there is no formal consensus criteria for diagnosing PDD, a new clinical diagnostic criteria has been proposed by the Movement Disorder Society. With recent advances in neuroimaging and molecular biological studies, understanding of the pathogenetic mechanisms has become possible. In addition to the Lewy bodies in these two disorders, senile plaques with amyloid appear in both. With the combination of Lewy bodies and senile plaques deposition, the clinical features of PDD and DLB prove more complex,which leads to diagnostic challenges between these two disorders. Finally, the therapeutic approaches to PDD and DLB are different from the treatments for Alzheimer\u2019s disease and Parkinson\u2019s disease.<\/p>\n

Keywords: Parkinson\u2019s disease with dementia, Dementia with Lewy bodies, Neuroimages, Pathology, Biomarkers, Diagnosis, Treatment<\/p>\n","protected":false},"excerpt":{"rendered":"

Chu-Yun Huang Department of Clinical pharmacy, Taipei M …<\/span> Read More →<\/span><\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144],"tags":[],"class_list":["post-2078","post","type-post","status-publish","format-standard","hentry","category-144"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t